Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Pharvaris, retaining the price target of $43.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given her Buy rating due to a combination of factors including the promising expectations from the Phase 3 RAPIDe-3 trial data anticipated in the fourth quarter of 2025. The trial is set to evaluate the effectiveness of deucrictibant for immediate relief during HAE attacks, with a high likelihood of success based on previous Phase 2 results.
Chatterjee notes that deucrictibant demonstrated consistent efficacy across various assessments, indicating a faster onset of relief compared to placebo. Despite potential biases in the open-label portion of the Phase 2 trial, the drug’s competitive profile and reliable benefits suggest it will perform well in the larger, blinded RAPIDe-3 trial, supporting the path towards approval.
In another report released on October 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.